Compare PDS & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | TRAX |
|---|---|---|
| Founded | 1951 | 2025 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1998 | 2026 |
| Metric | PDS | TRAX |
|---|---|---|
| Price | $85.09 | $34.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $100.96 | $72.50 |
| AVG Volume (30 Days) | 66.5K | ★ 992.4K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.01 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.68 | $15.69 |
| 52 Week High | $103.80 | $49.91 |
| Indicator | PDS | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 46.19 |
| Support Level | $82.18 | $15.69 |
| Resistance Level | $85.28 | $48.94 |
| Average True Range (ATR) | 2.57 | 2.82 |
| MACD | 0.26 | 0.06 |
| Stochastic Oscillator | 59.18 | 38.31 |
Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.